Harglim M 3 Forte Tablet SR is a combination oral antidiabetic medication containing Glimepiride 3 mg and Metformin 1000 mg, formulated for sustained release. It is primarily indicated for the management of type 2 diabetes mellitus in patients inadequately controlled by diet, exercise, and monotherapy. Glimepiride, a sulfonylurea class agent, enhances pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake. The sustained-release formulation ensures a gradual release of Metformin, minimizing gastrointestinal side effects commonly associated with immediate-release formulations. Harglim M 3 Forte Tablet SR should be administered orally with meals to improve gastrointestinal tolerance and optimize glycemic control. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or known hypersensitivity to its components. Regular monitoring of blood glucose, renal function, and hepatic parameters is recommended during therapy. Dose adjustments may be necessary based on glycemic response and tolerability. This combination therapy offers a synergistic approach to glycemic management, addressing both insulin secretion and insulin resistance, thereby improving overall glycemic control in type 2 diabetes patients.